Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Johnson & Johnson	Roche	Abbott Laboratories	Pfizer	Novartis
Symbol	NYSE:JNJ	OTCMKTS:RHHBY	NYSE:ABT	NYSE:PFE	NYSE:NVS
Price Information
Current Price	$170.22	$42.13	$118.31	$40.02	$88.96
52 Week Range	Buy	Hold	Buy	Hold	Hold
MarketRank™
Overall Score	2.3	1.4	2.2	2.1	2.0
Analysis Score	1.4	0.0	1.4	2.1	3.2
Community Score	2.5	2.4	2.8	2.9	2.3
Dividend Score	4.2	2.5	3.3	2.5	2.5
Ownership Score	1.7	0.0	1.7	1.7	0.0
Earnings & Valuation Score	1.9	1.9	1.9	1.3	1.9
Analyst Ratings
Consensus Recommendation	Buy	Hold	Buy	Hold	Hold
Consensus Price Target	$185.70	N/A	$125.81	$39.94	$108.50
% Upside from Price Target	9.09% upside	N/A	6.34% upside	-0.21% downside	21.96% upside
Trade Information
Market Cap	$448.26 billion	$288.53 billion	$210.22 billion	$223.22 billion	$203.60 billion
Beta	0.7	0.35	0.83	0.7	0.59
Average Volume	8,041,575	1,868,955	5,185,951	32,200,039	1,970,152
Sales & Book Value
Annual Revenue	$82.06 billion	$61.87 billion	$31.90 billion	$51.75 billion	$47.50 billion
Price / Sales	5.46	4.66	6.59	4.31	4.29
Cashflow	$12.42 per share	$3.06 per share	$5.30 per share	$4.46 per share	$7.53 per share
Price / Cash	13.71	13.77	22.31	8.97	11.82
Book Value	$22.60 per share	$5.27 per share	$17.70 per share	$11.46 per share	$24.53 per share
Price / Book	7.53	7.99	6.68	3.49	3.63
Profitability
Net Income	$15.12 billion	$13.58 billion	$3.69 billion	$16.27 billion	$11.73 billion
EPS	$8.68	$2.54	$3.24	$2.95	$5.24
Trailing P/E Ratio	26.76	16.59	62.60	25.82	28.79
Forward P/E Ratio	19.15	14.89	27.01	13.08	13.64
P/E Growth	3.06	3.69	2.06	2.79	1.76
Net Margins	21.01%	N/A	10.50%	17.85%	14.71%
Return on Equity (ROE)	34.64%	N/A	18.19%	24.88%	24.39%
Return on Assets (ROA)	13.40%	N/A	8.29%	9.32%	10.59%
Dividend
Annual Payout	$4.04	$0.77	$1.80	$1.56	$2.08
Dividend Yield	2.37%	1.83%	1.52%	3.90%	2.34%
Three-Year Dividend Growth	19.88%	N/A	35.85%	-10.94%	13.60%
Payout Ratio	46.54%	30.31%	55.56%	52.88%	39.69%
Years of Consecutive Dividend Growth	59 Years	N/A	49 Years	1 Years	1 Years
Debt
Debt-to-Equity Ratio	0.51%	0.36%	0.58%	0.76%	0.49%
Current Ratio	1.48%	1.23%	1.70%	1.40%	0.91%
Quick Ratio	1.24%	0.93%	1.19%	1.13%	0.69%
Ownership Information
Institutional Ownership Percentage	67.25%	0.32%	72.58%	67.36%	9.86%
Insider Ownership Percentage	0.27%	N/A	1.70%	0.08%	0.01%
Miscellaneous
Employees	134,500	101,465	109,000	78,500	105,794
Shares Outstanding	2.63 billion	6.85 billion	1.78 billion	5.58 billion	2.29 billion
Next Earnings Date	7/15/2021 (Estimated)	N/A	7/15/2021 (Estimated)	7/27/2021 (Estimated)	7/20/2021 (Estimated)
Optionable	Optionable	Not Optionable	Optionable	Optionable	Optionable

Source	Headline
	Novartis’s Piqray wins nod for breast cancer patients with gene-mutation - Korea Biomedical Review koreabiomed.com - May 14 at 2:10 AM
	Women's Health Beating Market By Excellent Revenue Growth: Novartis, Pfizer, Novo Nordisk – The Shotcaller - The Shotcaller theshotcaller.net - May 14 at 2:10 AM
	Novartis taps Ada Health's AI diagnosis platform for tracking rare, immunological conditions - FierceBiotech fiercebiotech.com - May 14 at 2:10 AM
	Fairhaven Wealth Management, LLC Buys ARK Innovation ETF, Netflix Inc, Novartis AG, Sells First ... gurufocus.com - May 13 at 2:18 PM
	Oxcarbazepine Tablets Market Share, Growth by Business Developments 2021 to 2027 – Novartis (Trileptal), Supernus Pharmaceuticals (Oxtellar XR), Apotex, Sun Pharm – The Shotcaller - The Shotcaller theshotcaller.net - May 13 at 12:41 PM
	Glaucoma Treatment Market Competitive Landscape Forecasts to 2027: Novartis AG, Allergan, Merck & Co., Inc., Akorn, Inc. – The Shotcaller - The Shotcaller theshotcaller.net - May 13 at 7:40 AM
	Global Corticosteroids Market Report 2021 Featuring Major Players - Sumitomo, Pfizer, Novartis, Merck, Sanofi, Johnson and Johnson, GSK, AstraZeneca, Cipla, and LEO Pharma - Yahoo Finance finance.yahoo.com - May 13 at 7:40 AM
	Worldwide Multiple Myeloma Treatment Industry to 2029 - Players Include Janssen Biotech, Bristol-Myers Squibb and Novartis Among Others - Yahoo Finance finance.yahoo.com - May 13 at 7:40 AM
	Ada Health partners with Novartis to work on diagnosis for immunological diseases - Mobihealth News mobihealthnews.com - May 13 at 7:40 AM
	Veterinary Ivermectin Market is set for Lucrative Growth \| Top Companies – Novartis AG, Intas Pharmaceuticals. – The Manomet Current - The Manomet Current manometcurrent.com - May 12 at 3:51 PM
	Global CAR-T Therapy Pipeline Market Analysis Report 2021-2030 Featuring Novartis, Kite Pharma, Pfizer, Juno Therapeutics, Celgene, CARsgen Therapeutics, Sorrento Therapeutics, and Legend Biotech - PRNewswire prnewswire.com - May 12 at 3:51 PM
	'Unbossing' Leaders at Novartis AG - Gallup gallup.com - May 12 at 3:51 PM
	Cullen Capital Management, LLC Buys JPMorgan Chase, BCE Inc, Novartis AG, Sells General Mills ... gurufocus.com - May 12 at 1:43 PM
	Global CAR-T Therapy Pipeline Market Analysis Report 2021-2030 Featuring Novartis, Kite Pharma, Pfizer, Juno Therapeutics, Celgene, CARsgen Therapeutics, Sorrento Therapeutics, and Legend Biotech - Yahoo Finance finance.yahoo.com - May 12 at 10:49 AM
	LoA Update: Novartis' approval likelihood for Entresto plummets by 11 points in acute myocardial - Clinical Trials Arena clinicaltrialsarena.com - May 12 at 10:49 AM
	Organ Transplantation Market to Witness Huge Growth by 2028 \| Novartis, Terumo, Roche – The Manomet Current - The Manomet Current manometcurrent.com - May 11 at 5:52 PM
	Rabies Vaccine for Humans Market Hissen, BCHT, Changsheng, Sanofi, Yisheng, Novartis, Prcmise, GlaxoSmithKline, Merck, Chengda, Wyeth pharmaceuticals, VACN, and More – The Manomet Current - The Manomet Current manometcurrent.com - May 11 at 5:52 PM
	Carcinoid Syndrome Management Market Impressive Gains including key players Novartis, Omega Laboratories, Teva Pharmaceutical – The Manomet Current - The Manomet Current manometcurrent.com - May 11 at 5:52 PM
	Novartis (NYSE:NVS) Rating Reiterated by Morgan Stanley americanbankingnews.com - May 11 at 5:02 PM
	Europe Intraocular Lens Market 2021 Precise Outlook – Novartis AG (Alcon), Bausch Health Companies Inc. (Bausch + Lomb), Carl Zeiss Meditec AG, EyeKon Medical Inc., Hoya Corporation, HumanOptics AG – The Shotcaller - The Shotcaller theshotcaller.net - May 11 at 12:43 PM
	Precision Medicine Market SWOT Analysis by Key Players- Pfizer, Novartis, Teva – The Shotcaller - The Shotcaller theshotcaller.net - May 11 at 7:43 AM
	Parkinsons disease Drug Market Is Booming Worldwide \| Teva, Novartis AG, GSK, AbbVie, Merck, Boehringer Ingelheim, Impax Laboratories – The Manomet Current - The Manomet Current manometcurrent.com - May 11 at 7:43 AM
	Megestrol Market Analysis and Research Report 2021 to 2026\| Novartis, Mylan, Mayne Pharma Inc, GSK, Pfizer, Gerui Pharmaceutical Company – The Shotcaller - The Shotcaller theshotcaller.net - May 11 at 7:43 AM
	Global Multiple Sclerosis Therapeutics Market Report 2021 Featuring AbbVie, Bayer, Biogen, Merck & Co, Novartis , Pfizer, Sanofi, & Teva Pharma - Market to Reach $22.3 Billion by 2027 - ResearchAndMarkets.com - Business Wire businesswire.com - May 11 at 7:43 AM
	Antibodies Market is set to Experience a Revolutionary growth by 2026-Novartis, F. Hoffmann-La Roche, Johnson & Johnson Services, Amgen – The Shotcaller - The Shotcaller theshotcaller.net - May 10 at 4:21 PM

Date	Company	Brokerage	Action
1/27/2021	Johnson & Johnson	JPMorgan Chase & Co.	Boost Price Target
1/27/2021	Johnson & Johnson	Credit Suisse Group	Boost Price Target
1/27/2021	Johnson & Johnson	Raymond James	Boost Price Target
1/27/2021	Johnson & Johnson	Cowen	Boost Price Target
1/27/2021	Johnson & Johnson	Morgan Stanley	Boost Price Target
1/27/2021	Johnson & Johnson	SVB Leerink	Boost Price Target
1/27/2021	Johnson & Johnson	Wells Fargo & Company	Boost Price Target
1/26/2021	Johnson & Johnson	Cantor Fitzgerald	Boost Price Target
8/19/2020	Johnson & Johnson	Stifel Nicolaus	Downgrade
7/20/2020	Johnson & Johnson	Bank of America	Reiterated Rating
7/20/2020	Johnson & Johnson	Independent Research	Upgrade
7/17/2020	Johnson & Johnson	Citigroup	Boost Price Target
4/29/2020	Johnson & Johnson	Barclays	Boost Price Target
3/16/2021	Roche	Jefferies Financial Group	Downgrade
3/5/2021	Roche	Erste Group	Downgrade
2/25/2021	Roche	Berenberg Bank	Reiterated Rating
2/17/2021	Roche	UBS Group	Downgrade
2/4/2021	Roche	Oddo Bhf	Downgrade
1/15/2021	Roche	Deutsche Bank Aktiengesellschaft	Initiated Coverage
9/28/2020	Roche	Societe Generale	Reiterated Rating
7/13/2020	Roche	Sanford C. Bernstein	Initiated Coverage
7/3/2020	Roche	AlphaValue	Upgrade
5/13/2020	Roche	Wolfe Research	Upgrade
4/30/2020	Roche	HSBC	Upgrade
4/21/2021	Abbott Laboratories	Atlantic Securities	Initiated Coverage
4/20/2021	Abbott Laboratories	William Blair	Reiterated Rating
1/28/2021	Abbott Laboratories	BTIG Research	Upgrade
9/2/2020	Abbott Laboratories	The Goldman Sachs Group	Set Price Target
5/12/2021	Pfizer	Mizuho	Reiterated Rating
4/7/2021	Pfizer	Royal Bank of Canada	Initiated Coverage
2/3/2021	Pfizer	DZ Bank	Reiterated Rating
3/16/2021	Novartis	Argus	Reiterated Rating

(Data available from 5/15/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources